EN DE
Watch Bioceltix S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bioceltix S.A. (BCX) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Bioceltix S.A. stock PLN 46.51, price PLN 67.00, that is 30.6% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLBCLTX00019

BS Bioceltix S.A. logo Thin data Nov 16, 2026

Bioceltix S.A.

BCX · WAR

Expensive (fair value 31% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Quality 40/100 
Mixed vs. peers (3/6) 
Fair value 46.51 PLN · Overvalued 
Falling price (downtrend) 
Weak Growth 
Negative free cash flow 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch Bioceltix S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

126.80 PLN 29.70 PLN Fair Value 46.51 PLN Nov 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 29.70 PLN – 126.80 PLN · fair‑value band 34.88 PLN – 58.14 PLN · the 67.00 PLN price screens above the 46.51 PLN fair value. As of Nov 16, 2026.

Follow Bioceltix in your weekly email

Every Wednesday you see whether Bioceltix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use.

Show moreShow less

The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses.

The company was founded in 2016 and is headquartered in Wroclaw, Poland.

Stock analysis

Bioceltix S.A. (BCX) currently trades at 67.00 PLN, while our estimate is 46.51 PLN, 31% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 34.88 PLN (bear) to 58.14 PLN (bull), the price of 67.00 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Bioceltix S.A. reported revenue of 0 PLN in FY2025 versus 0 PLN in FY2021. Reported net income was −15.2M PLN in FY2025.

Key figures

Market cap 371M PLN (≈ $92.5M) Micro · EPS (TTM) −3.47 PLN · Return on equity −39.5% · Return on assets (EBIT) −85.3% (5-year average) · Free cash flow −13.9M PLN · Net cash 68.1M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −31%, BCX screens richer than that median.

Fair Value

Bear 34.88 PLN Fair Value 46.51 PLN Bull 58.14 PLN
Price 67.00 PLN · Downside -30.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 19
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 54
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BCX screens overvalued: fair value 31% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Bioceltix S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 3/4 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside −32.4% · Below median
Profitability
Return on assets −20.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.30× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs BCX
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs BCX
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs BCX
argenx SE ARGX $950.95 $908.40 −4% vs BCX
CSL Limited CSL A$199.55 A$186.49 −7% vs BCX
Moderna, Inc MRNA $215.27 $135.64 −37% vs BCX
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs BCX
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs BCX
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs BCX
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs BCX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bioceltix S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bioceltix S.A. Fair Value". https://www.fairvalue-calculator.com/stock/BCX

Frequently asked questions

Is Bioceltix S.A. (BCX) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 46.51 PLN versus a price of 67.00 PLN, about 31% lower (overvalued).
What is the fair value of BCX?
Our estimate for Bioceltix S.A. is 46.51 PLN (as of Nov 16, 2026), built from audited fundamentals. The current price: 67.00 PLN.
What is the quality score of BCX?
Bioceltix S.A. has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioceltix S.A. (BCX)?
Our calculated price target is the estimate of 46.51 PLN (as of Nov 16, 2026). Cautious scenario 34.88 PLN, optimistic scenario 58.14 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Bioceltix S.A. stock forecast for 2026?
Our estimate puts fair value at 46.51 PLN, about 31% lower versus a price of 67.00 PLN (overvalued). Cautious scenario 34.88 PLN, optimistic scenario 58.14 PLN. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Bioceltix S.A. (BCX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bioceltix S.A. it is 46.51 PLN per share (as of Nov 16, 2026), against a price of 67.00 PLN.
Is Bioceltix S.A. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, BCX trades above its calculated fair value: price 67.00 PLN, fair value 46.51 PLN, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BCX?
No. The price is what the market pays today (67.00 PLN); the fair value is what the company's own numbers justify (46.51 PLN). For Bioceltix S.A. the two are 20.49 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Bioceltix S.A. worth?
The market values Bioceltix S.A. at about 371M PLN (market capitalisation, as of Nov 16, 2026). Per share that is 67.00 PLN; our models calculate a fair value of 46.51 PLN per share.
What do the bullish and bearish scenarios say about BCX?
Our models span a range for Bioceltix S.A.: cautious scenario 34.88 PLN, base 46.51 PLN, optimistic 58.14 PLN per share (as of Nov 16, 2026, price 67.00 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bioceltix S.A. (BCX)?
Balance-sheet figures for Bioceltix S.A. (as of Nov 16, 2026): return on equity −39.5%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is BCX from its 52-week high?
Bioceltix S.A. trades at 67.00 PLN, about 32% below its 52-week high of 98.00 PLN and 13% above the low of 59.50 PLN (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 46.51 PLN is for.
Which stocks are comparable to Bioceltix S.A.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bioceltix S.A. stock attractive at the current price?
The data as of Nov 16, 2026: price 67.00 PLN, calculated fair value 46.51 PLN (−31%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Bioceltix S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bioceltix S.A. (BCX)?
The closing price on Nov 17, 2026 was 67.00 PLN. Our estimate is 46.51 PLN, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bioceltix S.A. right now?
The price sits above even our optimistic bull case (58.14 PLN). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Bioceltix S.A.

How large is the market capitalisation of Bioceltix S.A. (BCX)?
The market capitalisation of Bioceltix S.A. is 371M PLN (≈ $92.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Bioceltix S.A. (BCX)?
Earnings per share at Bioceltix S.A. are −3.47 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Bioceltix S.A. (BCX)?
The return on equity (ROE) of Bioceltix S.A. is −39.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bioceltix S.A. (BCX)?
On an EBIT basis the return on assets of Bioceltix S.A. is −85.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Bioceltix S.A. (BCX) generate?
The free cash flow of Bioceltix S.A. is −13.9M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Bioceltix S.A. (BCX) hold?
Bioceltix S.A. holds more cash than debt, 68.1M PLN net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Bioceltix S.A. in the live analysis

One click puts Bioceltix S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.